Skip to content
OpenCapital
Get started

Innoviva, Inc. INVA Acquired in-process research and development

Acquired in-process research and development at other companies

Organon logo
OrganonOGN
$10M0.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$228.9M+1.6%

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B—
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K—
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.41B+9.7%
P/E3.5×—
P/S4.2×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%—
Debt / equity0.2×—
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The official record: Innoviva, Inc.’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s acquired in-process research and development?
Innoviva, Inc. (INVA) reported acquired in-process research and development of $2.34M in Q4 2025.
What does acquired in-process research and development mean?
This metric tracks the cash outflows dedicated to acquiring research and development projects that are currently in progress but have not yet reached commercial viability. It serves as a key indicator of a company's commitment to long-term innovation and its strategy for expanding its product pipeline through external acquisition rather than internal development. High levels of spending in this area suggest an aggressive growth strategy focused on future therapeutic or technological breakthroughs.